Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    New navigation/help items were added, including Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study, and the Intervention/Treatment heading was standardized (Intervention / Treatment vs Intervention/Treatment). The page revision tag was updated from v3.5.5 to v3.6.0.
    Difference
    0.4%
    Check dated 2026-06-13T04:45:01.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Footer revision tag updated from v3.5.4 to v3.5.5, indicating a new site version.
    Difference
    0.0%
    Check dated 2026-06-05T22:11:37.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    A new revision entry (v3.5.4) was added to the page, replacing the previous revision (v3.5.3) in the study record’s history.
    Difference
    0.0%
    Check dated 2026-05-15T11:30:56.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s study page footer was updated to reflect a new site revision version (v3.5.3 instead of v3.5.2), with no visible change to the trial’s study details.
    Difference
    0.0%
    Check dated 2026-04-24T06:27:53.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    Page revision tag updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:44:06.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T05:10:52.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.